IPOX Schuster LLC


IPOX Breaking News: Novartis enters deal to acquire IPOX 100 U.S. Portfolio Holding AveXis at 85% premium / ETF in focus: FPX

IPOX Schuster LLC (www.ipox.com), the innovative Financial Services Firm behind the IPOX Indexes, is pleased to note news about the definite acquisition of biotech AveXis (AVXS) by Swiss pharma giant Novartis for USD billion 8.7, a 85% premium to Friday’s close.

AveXis (AVXS) is a portolio holding in a number of IPOX Indexes, including the IPOX 100 U.S. (IPXO).

The IPOX 100 U.S. (IPXO) is tracked by the USD billion 1.1, 5-star First Trust Equity Opportunities ETF (FPX).

Best Regards

The IPOX Team

Filed under News